Tengion is a leading clinical-stage regenerative medicine company focused on the development of its pioneering Organ Regeneration Platform. This platform is intended to harness the body’s intrinsic regenerative pathways to regenerate an array of native-like organs and tissues, with the aim of delaying or eliminating the need for chronic disease therapies, organ transplantation and anti-rejection medication. The company’s most advanced product candidate, the Neo-Urinary Conduit, is currently undergoing an initial clinical trial. For more information, visit the company’s Web site at www.tengion.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: